Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
Hai | vor ungefähr 12 Monaten |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
Hai | translation missing: de.datetime.time_ago_in_words.almost_x_years |
| Titel | Datum |
|---|---|
| CATABASIS PHARMACEUTICALS INC - 8-K, Current Report | vor ungefähr 2 Monaten |
| Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know | vor ungefähr 2 Monaten |
| Catabasis Pharmaceuticals, iBio leads healthcare gainers; Ovid Therapeutics, Auris Medical among major losers | vor ungefähr 2 Monaten |
| Pre-market Movers In Healthcare Sector: DBVT, ACOR, ANPC, AGRX, CATB… | vor ungefähr 3 Monaten |
| Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma | vor ungefähr 3 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |